[Market Focus] Neuromeka Surpasses Conventional Robot Limits, Attracts Global Adoption Inquiries

The stock price of Neuromeka, a company specializing in robotic automation solutions, has surged after unveiling its next-generation humanoid robot platform, EIR, at CES 2026 in Las Vegas, USA. Investor sentiment appears to have been boosted by the news that Samsung Asset Management holds a 5.04% stake in the company.

Last year, Neuromeka's stock did not rise as much as its major competitors, such as Doosan Robotics, Rainbow Robotics, and Robotis. Robotis saw a 980% increase compared to the end of 2024, and Rainbow Robotics rose by about 180%. During the same period, Neuromeka's stock increased by 31%.

As of 2:40 p.m. on January 13, Neuromeka was trading at 38,650 won, up 15.89% from the previous trading day.

On this day, Samsung Asset Management disclosed that it holds a 5.04% stake (573,792 shares) in Neuromeka. The company stated that the acquisition was for "investment purposes only."

According to its quarterly report, Neuromeka explained that it has secured a differentiated competitive edge in the market through internalization of core components, proprietary control technology, price competitiveness, and diversification of its business portfolio.

Previously at CES, Neuromeka showcased its "Zero-shot Pick & Place" technology through EIR equipped with its deep learning-based vision solution, enabling the robot to recognize and manipulate target objects without any prior training. This is a clear technological distinction from the "imitation learning" models presented by many robot companies from countries such as China, which require training on massive amounts of data. The zero-shot technology, which overcomes the limitations of conventional robots, has drawn significant global attention.

The core strength of EIR lies in its ability to flexibly respond on-site. This is based on Neuromeka's Vision Foundation Model (VFM). Unlike existing humanoid robots that can only handle pre-set objects, EIR, through VFM, can understand user language commands and accurately infer the target object among numerous items, autonomously calculating the optimal grip position even for objects it has never encountered before.

With the public release of its unique zero-shot technology and commercialization roadmap, Neuromeka has received concrete inquiries from global companies regarding adoption. During the first two days of the event (January 6-7), Neuromeka held more than 10 meetings with major companies in North America and Europe regarding adoption and partnership opportunities.

Neuromeka is discussing the introduction of automated sorting processes for casting parts using humanoids with Company C in the United States, and the supply of service robots for a robot cafe in Atlanta Town Center with Company P. In addition, the company has established a pipeline of discussions on comprehensive commercialization possibilities, including cooperation on sales networks in North America with global healthcare company A, and a partnership in Europe with Italian energy company G, spanning manufacturing, service, and healthcare sectors.